Werewolf Therapeutics Inc
NASDAQ:HOWL

Watchlist Manager
Werewolf Therapeutics Inc Logo
Werewolf Therapeutics Inc
NASDAQ:HOWL
Watchlist
Price: 1.9 USD 6.74% Market Closed
Market Cap: 84.7m USD
Have any thoughts about
Werewolf Therapeutics Inc?
Write Note

Werewolf Therapeutics Inc
Cash from Financing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Werewolf Therapeutics Inc
Cash from Financing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
Werewolf Therapeutics Inc
NASDAQ:HOWL
Cash from Financing Activities
$58.4m
CAGR 3-Years
-15%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Cash from Financing Activities
-$2.8B
CAGR 3-Years
45%
CAGR 5-Years
25%
CAGR 10-Years
1%
Gilead Sciences Inc
NASDAQ:GILD
Cash from Financing Activities
-$6.8B
CAGR 3-Years
0%
CAGR 5-Years
4%
CAGR 10-Years
-3%
Amgen Inc
NASDAQ:AMGN
Cash from Financing Activities
-$5.3B
CAGR 3-Years
0%
CAGR 5-Years
21%
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash from Financing Activities
-$1.2B
CAGR 3-Years
1%
CAGR 5-Years
-55%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash from Financing Activities
-$1.5B
CAGR 3-Years
-55%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Werewolf Therapeutics Inc
Glance View

Market Cap
83.1m USD
Industry
Biotechnology

Werewolf Therapeutics, Inc. is a biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 39 full-time employees. The company went IPO on 2021-04-30. The firm is focused on developing a pipeline of cancer treatments. The company is developing immuno-stimulatory therapeutics designed to act selectively within the tumor microenvironment to enhance the body’s immune response to cancer. Its PREDATOR platform is designed to conditionally activate molecules that stimulate both adaptive and innate immunity while addressing the limitations of conventional proinflammatory immune therapies. The INDUKINETM molecules, are intended to selectively target the tumor microenvironment (TME). PREDATOR platform consists of protein engineering technologies which are used to generate INDUKINE molecules with multiple functional domains rationally engineered into a single protein to achieve the pharmaceutical profile. The firm using PREDATOR platform, has developed three initial product candidates: WTX-124, WTX-330 and WTX-613.

HOWL Intrinsic Value
1.49 USD
Overvaluation 21%
Intrinsic Value
Price

See Also

What is Werewolf Therapeutics Inc's Cash from Financing Activities?
Cash from Financing Activities
58.4m USD

Based on the financial report for Dec 31, 2023, Werewolf Therapeutics Inc's Cash from Financing Activities amounts to 58.4m USD.

What is Werewolf Therapeutics Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 3Y
-15%

Over the last year, the Cash from Financing Activities growth was 267%. The average annual Cash from Financing Activities growth rates for Werewolf Therapeutics Inc have been -15% over the past three years .

Back to Top